vs
EDGEWELL PERSONAL CARE Co（EPC）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
Royalty Pharma plc的季度营收约是EDGEWELL PERSONAL CARE Co的1.5倍（$622.0M vs $422.8M），Royalty Pharma plc净利率更高（34.4% vs -15.5%，领先50.0%），Royalty Pharma plc同比增速更快（4.8% vs -11.6%），过去两年Royalty Pharma plc的营收复合增速更高（4.6% vs -16.0%）
Edgewell个人护理是一家总部位于美国康涅狄格州谢尔顿的跨国消费品企业，主营业务聚焦个人护理产品领域。公司在2015年从劲量控股分拆后正式成立，目前在全球多个市场开展个人护理相关业务。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
EPC vs RPRX — 直观对比
营收规模更大
RPRX
是对方的1.5倍
$422.8M
营收增速更快
RPRX
高出16.4%
-11.6%
净利率更高
RPRX
高出50.0%
-15.5%
两年增速更快
RPRX
近两年复合增速
-16.0%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $422.8M | $622.0M |
| 净利润 | $-65.7M | $214.2M |
| 毛利率 | 38.1% | — |
| 营业利润率 | -4.5% | 62.4% |
| 净利率 | -15.5% | 34.4% |
| 营收同比 | -11.6% | 4.8% |
| 净利润同比 | -3028.6% | 2.9% |
| 每股收益（稀释后） | $-1.41 | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EPCRPRX
| Q4 25 | $422.8M | $622.0M | ||
| Q3 25 | $600.5M | $609.3M | ||
| Q2 25 | $627.2M | $578.7M | ||
| Q1 25 | $580.7M | $568.2M | ||
| Q4 24 | $415.1M | $593.6M | ||
| Q3 24 | $517.6M | $564.7M | ||
| Q2 24 | $647.8M | $537.3M | ||
| Q1 24 | $599.4M | $568.0M |
净利润EPCRPRX
| Q4 25 | $-65.7M | $214.2M | ||
| Q3 25 | $-30.6M | $288.2M | ||
| Q2 25 | $29.1M | $30.2M | ||
| Q1 25 | $29.0M | $238.3M | ||
| Q4 24 | $-2.1M | $208.2M | ||
| Q3 24 | $8.8M | $544.0M | ||
| Q2 24 | $49.0M | $102.0M | ||
| Q1 24 | $36.0M | $4.8M |
毛利率EPCRPRX
| Q4 25 | 38.1% | — | ||
| Q3 25 | 37.9% | — | ||
| Q2 25 | 42.8% | — | ||
| Q1 25 | 44.1% | — | ||
| Q4 24 | 41.6% | — | ||
| Q3 24 | 41.1% | — | ||
| Q2 24 | 44.3% | — | ||
| Q1 24 | 43.1% | — |
营业利润率EPCRPRX
| Q4 25 | -4.5% | 62.4% | ||
| Q3 25 | -4.2% | 70.1% | ||
| Q2 25 | 8.6% | 36.3% | ||
| Q1 25 | 10.1% | 94.0% | ||
| Q4 24 | 2.2% | 60.9% | ||
| Q3 24 | 3.9% | — | ||
| Q2 24 | 12.8% | 50.2% | ||
| Q1 24 | 11.7% | -13.0% |
净利率EPCRPRX
| Q4 25 | -15.5% | 34.4% | ||
| Q3 25 | -5.1% | 47.3% | ||
| Q2 25 | 4.6% | 5.2% | ||
| Q1 25 | 5.0% | 41.9% | ||
| Q4 24 | -0.5% | 35.1% | ||
| Q3 24 | 1.7% | 96.3% | ||
| Q2 24 | 7.6% | 19.0% | ||
| Q1 24 | 6.0% | 0.8% |
每股收益（稀释后）EPCRPRX
| Q4 25 | $-1.41 | $0.49 | ||
| Q3 25 | $-0.65 | $0.67 | ||
| Q2 25 | $0.62 | $0.07 | ||
| Q1 25 | $0.60 | $0.55 | ||
| Q4 24 | $-0.04 | $0.46 | ||
| Q3 24 | $0.18 | $1.21 | ||
| Q2 24 | $0.98 | $0.23 | ||
| Q1 24 | $0.72 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $618.7M |
| 总债务越低越好 | $1.5B | $9.0B |
| 股东权益账面价值 | $1.5B | $9.7B |
| 总资产 | $3.8B | $19.6B |
| 负债/权益比越低杠杆越低 | 1.03× | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资EPCRPRX
| Q4 25 | — | $618.7M | ||
| Q3 25 | — | $938.9M | ||
| Q2 25 | — | $631.9M | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | — | $929.0M | ||
| Q3 24 | $209.1M | $950.1M | ||
| Q2 24 | — | $1.8B | ||
| Q1 24 | — | $843.0M |
总债务EPCRPRX
| Q4 25 | $1.5B | $9.0B | ||
| Q3 25 | $1.4B | $8.9B | ||
| Q2 25 | $1.4B | $8.0B | ||
| Q1 25 | $1.4B | $7.6B | ||
| Q4 24 | $1.4B | $7.6B | ||
| Q3 24 | $1.3B | $7.6B | ||
| Q2 24 | $1.3B | $7.6B | ||
| Q1 24 | $1.4B | $6.1B |
股东权益EPCRPRX
| Q4 25 | $1.5B | $9.7B | ||
| Q3 25 | $1.6B | $9.6B | ||
| Q2 25 | $1.6B | $9.5B | ||
| Q1 25 | $1.5B | $9.8B | ||
| Q4 24 | $1.5B | $10.3B | ||
| Q3 24 | $1.6B | $10.3B | ||
| Q2 24 | $1.6B | $9.8B | ||
| Q1 24 | $1.6B | $9.9B |
总资产EPCRPRX
| Q4 25 | $3.8B | $19.6B | ||
| Q3 25 | $3.8B | $19.3B | ||
| Q2 25 | $3.8B | $18.3B | ||
| Q1 25 | $3.8B | $17.6B | ||
| Q4 24 | $3.7B | $18.2B | ||
| Q3 24 | $3.7B | $18.0B | ||
| Q2 24 | $3.7B | $17.7B | ||
| Q1 24 | $3.8B | $16.1B |
负债/权益比EPCRPRX
| Q4 25 | 1.03× | 0.92× | ||
| Q3 25 | 0.89× | 0.93× | ||
| Q2 25 | 0.88× | 0.84× | ||
| Q1 25 | 0.95× | 0.78× | ||
| Q4 24 | 0.97× | 0.74× | ||
| Q3 24 | 0.81× | 0.74× | ||
| Q2 24 | 0.82× | 0.78× | ||
| Q1 24 | 0.88× | 0.62× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-125.9M | $827.1M |
| 自由现金流经营现金流 - 资本支出 | $-137.5M | — |
| 自由现金流率自由现金流/营收 | -32.5% | — |
| 资本支出强度资本支出/营收 | 2.7% | — |
| 现金转化率经营现金流/净利润 | — | 3.86× |
| 过去12个月自由现金流最近4个季度 | $36.3M | — |
8季度趋势，按日历期对齐
经营现金流EPCRPRX
| Q4 25 | $-125.9M | $827.1M | ||
| Q3 25 | $74.1M | $702.6M | ||
| Q2 25 | $114.8M | $364.0M | ||
| Q1 25 | $45.1M | $596.1M | ||
| Q4 24 | $-115.6M | $742.5M | ||
| Q3 24 | $-388.3M | $703.6M | ||
| Q2 24 | $101.2M | $658.2M | ||
| Q1 24 | $129.0M | $664.6M |
自由现金流EPCRPRX
| Q4 25 | $-137.5M | — | ||
| Q3 25 | $46.5M | — | ||
| Q2 25 | $99.3M | — | ||
| Q1 25 | $28.0M | — | ||
| Q4 24 | $-132.4M | — | ||
| Q3 24 | $-414.2M | — | ||
| Q2 24 | $88.6M | — | ||
| Q1 24 | $117.5M | — |
自由现金流率EPCRPRX
| Q4 25 | -32.5% | — | ||
| Q3 25 | 7.7% | — | ||
| Q2 25 | 15.8% | — | ||
| Q1 25 | 4.8% | — | ||
| Q4 24 | -31.9% | — | ||
| Q3 24 | -80.0% | — | ||
| Q2 24 | 13.7% | — | ||
| Q1 24 | 19.6% | — |
资本支出强度EPCRPRX
| Q4 25 | 2.7% | — | ||
| Q3 25 | 4.6% | — | ||
| Q2 25 | 2.5% | — | ||
| Q1 25 | 2.9% | — | ||
| Q4 24 | 4.0% | — | ||
| Q3 24 | 5.0% | — | ||
| Q2 24 | 1.9% | — | ||
| Q1 24 | 1.9% | — |
现金转化率EPCRPRX
| Q4 25 | — | 3.86× | ||
| Q3 25 | — | 2.44× | ||
| Q2 25 | 3.95× | 12.06× | ||
| Q1 25 | 1.56× | 2.50× | ||
| Q4 24 | — | 3.57× | ||
| Q3 24 | -44.13× | 1.29× | ||
| Q2 24 | 2.07× | 6.45× | ||
| Q1 24 | 3.58× | 139.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EPC
| Other | $242.0M | 57% |
| Sunand Skin Care Segment | $131.5M | 31% |
| Shavinggelsandcreams | $32.3M | 8% |
| Wipes And Other Skin Care Products | $17.0M | 4% |
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
